Ingredient commercialisation pioneer joins Evolva

Previously drove significant revenue growth at Martek.

19 May 2016 – Evolva (SIX: EVE) announces that Angela Tsetsis will join the Evolva Commercial Team as Senior VP, Ingredient Solutions, Health & Wellness. Angela started her career as an engineer at Kidde Consultants and J.L. Wickam Company before joining Martek Biosciences, where she rose to VP, Corporate Strategy.

Angela was instrumental in launching Martek’s first consumer branded dietary supplement, which became a key ingredient in infant formulas with more than USD 350 million in annual revenues. Martek was eventually acquired by DSM for USD 1.1 billion.

After Martek, Angela became CEO of Fluxome where she pioneered the commercial development of fermentation produced ingredients.  Most recently she was President of Vizuri Health Sciences, a US-based biotech focused on developing natural ingredients for cosmetic, nutrition, personal care, and pharmaceutical applications.

– ends –

Download press release in English
Download press release in German

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see Questions about our fermentation approach? Have a look at our video.
Contact Details

Neil Goldsmith
+ 41 61 485 2005
Jakob Dynnes Hansen
+ 41 61 485 2034
Paul Verbraeken
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.